Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in Asian patients with ASCVD or high risk and elevated LDL-C
NCT04765657Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 4
01
Overview
A Phase 3 trial of inclisiran in hypercholesterolemia, sponsored by Novartis. Started Mar 2021; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04765657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04765657.